Infliximab

What is Infliximab?

Infliximab is a powerful pharmaceutical compound classified as a chimeric monoclonal antibody, specifically targeting tumor necrosis factor alpha (TNF-alpha). This potent biologic medication is widely recognized by its brand name Remicade, among others, and plays a crucial role in managing various chronic inflammatory and autoimmune diseases. It was first approved by the U.S. Food and Drug Administration (FDA) in 1998, marking a significant advancement in the treatment landscape for conditions that were previously challenging to manage effectively.

As a TNF-alpha inhibitor, Infliximab functions by neutralizing the pro-inflammatory cytokine TNF-alpha, which is a key mediator in the inflammatory processes characteristic of many autoimmune disorders. By binding to both soluble and transmembrane forms of TNF-alpha, Infliximab prevents it from interacting with its receptors, thereby reducing inflammation and preventing further tissue damage. Its development represented a paradigm shift, moving from broad immunosuppression to more targeted biological therapies that specifically address the underlying molecular pathways of disease.

Belonging to the ATC code L04AB02 (Immunosuppressants, TNF-alpha inhibitors), Infliximab is administered intravenously, typically in a hospital or clinic setting. Its chimeric nature means it is composed of both human and mouse protein sequences, designed to minimize immunogenicity while maximizing therapeutic efficacy. This innovative approach has made Infliximab an indispensable treatment option for millions of patients worldwide, offering relief from debilitating symptoms and improving their quality of life.

⚙️ Mechanism of Action

The primary mechanism of action of Infliximab revolves around its high affinity and specificity for tumor necrosis factor alpha (TNF-alpha). TNF-alpha is a pleiotropic cytokine that plays a central role in initiating and perpetuating inflammation in numerous autoimmune and inflammatory diseases. In conditions such as Crohn's disease, rheumatoid arthritis, and psoriasis, TNF-alpha is overexpressed and contributes significantly to the pathological processes, including cellular infiltration, tissue destruction, and systemic symptoms. Infliximab acts by binding to both soluble and cell-surface bound forms of human TNF-alpha, effectively neutralizing its biological activity. This binding prevents TNF-alpha from interacting with its receptors on target cells, thereby inhibiting the downstream signaling pathways that lead to inflammation and immune cell activation.

Beyond simple neutralization, Infliximab also induces several other immunomodulatory effects. It can mediate lysis of TNF-alpha-producing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Furthermore, Infliximab can induce apoptosis (programmed cell death) in activated immune cells, particularly T-lymphocytes and macrophages that express membrane-bound TNF-alpha. This multi-faceted approach helps to reduce the inflammatory burden, slow disease progression, and promote tissue healing. The precise molecular interactions involving the Fc region of Infliximab with Fc receptors on immune cells contribute to its comprehensive therapeutic profile.

• Infliximab binds with high affinity to both soluble and transmembrane forms of human TNF-alpha.
• It neutralizes TNF-alpha's biological activity, preventing it from binding to its receptors.
• Infliximab induces apoptosis in TNF-alpha-expressing cells, reducing the inflammatory cell population.
• It mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against cells expressing membrane-bound TNF-alpha.
• By blocking TNF-alpha, Infliximab reduces the production of other pro-inflammatory cytokines and adhesion molecules.

🏥️ Medical Uses & Indications

Infliximab is a cornerstone in the treatment of various chronic inflammatory and autoimmune conditions, offering significant relief and disease control for patients who have not responded adequately to conventional therapies. Its broad spectrum of action against TNF-alpha allows it to address the underlying inflammation in diverse organ systems, leading to improved symptoms, reduced disease activity, and enhanced quality of life. The decision to initiate Infliximab therapy is typically made after careful consideration by a specialist, weighing the potential benefits against the risks for each individual patient.

Primary Indications

• Crohn's Disease (Adult and Pediatric): For reducing signs and symptoms, inducing and maintaining clinical remission, and promoting mucosal healing in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.
• Ulcerative Colitis (Adult and Pediatric): For reducing signs and symptoms, inducing and maintaining clinical remission, and promoting mucosal healing in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
• Rheumatoid Arthritis (Adult): In combination with methotrexate, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
• Ankylosing Spondylitis (Adult): For reducing signs and symptoms in adult patients with active ankylosing spondylitis.
• Psoriatic Arthritis (Adult): For reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
• Plaque Psoriasis (Adult): For the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

Secondary / Off-label Uses

• Behcet's Disease: Particularly for refractory ocular manifestations or severe gastrointestinal involvement.
• Sarcoidosis: For patients with severe, chronic sarcoidosis, especially those with pulmonary or ocular involvement, who are refractory to conventional treatments.
• Refractory Uveitis: In cases of non-infectious uveitis that are resistant to standard immunosuppressive therapies.

💊 Dosage & Administration

Infliximab is administered as an intravenous (IV) infusion, typically over a period of at least two hours. The dosage regimen for Infliximab usually involves an induction phase followed by a maintenance phase. The initial doses are given at weeks 0, 2, and 6 to achieve rapid therapeutic levels, after which maintenance doses are administered less frequently. The specific dose and frequency depend on the patient's weight, the indication being treated, and their response to therapy. Patients are closely monitored during and after the infusion for any signs of infusion reactions.

Important: Always follow your prescriber instructions. Dosages vary by weight, age, and condition, and may be adjusted based on clinical response and serum drug levels. Do not attempt to self-administer or alter your prescribed dose of Infliximab.

⚠️ Side Effects

Like all potent medications, Infliximab can cause side effects. Patients receiving Infliximab should be closely monitored by their healthcare provider for the duration of their treatment. The risk of side effects should always be weighed against the significant benefits Infliximab can provide in managing severe inflammatory conditions.

Common Side Effects (>10%)

• Infusion-related reactions (e.g., fever, chills, headache, rash, itching, chest pain, hypotension/hypertension)
• Upper respiratory tract infections (e.g., sinusitis, pharyngitis)
• Headache
• Nausea
• Abdominal pain
• Rash

Less Common (1-10%)

• Fatigue
• Dizziness
• Elevated liver enzymes
• Hypertension
• Bronchitis
• Urinary tract infection

Rare but Serious

• Serious Infections: Due to its immunosuppressive effects, Infliximab increases the risk of serious infections, including reactivation of latent tuberculosis, fungal infections (e.g., histoplasmosis), bacterial sepsis, and opportunistic infections. Patients should be screened for latent TB before starting therapy.
• Malignancy: There is an increased risk of certain malignancies, including lymphoma and skin cancers, particularly in children and adolescents. Close monitoring is essential during treatment with Infliximab.
• Heart Failure Exacerbation: Infliximab can worsen existing heart failure. It is contraindicated in patients with moderate to severe heart failure (NYHA Class III/IV).

🔄 Drug Interactions

Concomitant use of Infliximab with certain other medications can lead to significant drug interactions, potentially increasing the risk of adverse effects or altering the efficacy of either drug. It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting or during Infliximab therapy to ensure proper management and avoid complications.

• Live Vaccines: Administration of live vaccines (e.g., MMR, varicella, yellow fever) during Infliximab therapy is generally not recommended due to the increased risk of infection in immunosuppressed patients.
• Other Biologic Agents: Concomitant use with other TNF-alpha inhibitors (e.g., adalimumab, etanercept) or other biologics that suppress the immune system (e.g., anakinra, abatacept) is not recommended due to an increased risk of serious infections and other adverse events.
• Immunosuppressants: While often used in combination with methotrexate, azathioprine, or mercaptopurine in certain indications to enhance efficacy and reduce immunogenicity, careful monitoring is required due to the increased risk of myelosuppression and serious infections.
• Cytokines: Co-administration with other cytokines or immunomodulators might alter the immune response and safety profile, requiring caution.
• Warfarin: Changes in inflammatory status can affect the activity of cytochrome P450 enzymes, which metabolize warfarin. Patients on warfarin may require closer monitoring of their INR when starting or stopping Infliximab.
• Rituximab: While not a direct contraindication, combining Infliximab with B-cell depleting agents like rituximab should be done with caution due to enhanced immunosuppression and infection risk.

🚫 Contraindications & Warnings

• Severe Heart Failure: Infliximab is contraindicated in patients with moderate to severe (NYHA Class III/IV) heart failure due to the risk of exacerbating the condition.
• Active Serious Infections: Patients with active serious infections, including sepsis, abscesses, opportunistic infections, or tuberculosis, should not start Infliximab therapy until the infection is controlled.
• Hypersensitivity: A history of hypersensitivity reactions to Infliximab or any of its excipients is a contraindication.
• Demyelinating Disease: Use of TNF-alpha inhibitors, including Infliximab, has been associated with new onset or exacerbation of central nervous system demyelinating disorders (e.g., multiple sclerosis).
• Live Vaccinations: Avoid live vaccines during treatment with Infliximab due to the risk of infection.
• Hepatitis B Reactivation: Screening for Hepatitis B virus (HBV) infection is recommended before starting Infliximab, as it can cause HBV reactivation in chronic carriers.

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. The content provided here is not a substitute for professional medical advice, diagnosis, or treatment.

❓ Frequently Asked Questions

Is Infliximab safe for long-term use?

Infliximab is often used for long-term management of chronic autoimmune diseases. While generally considered safe and effective for prolonged use under medical supervision, it does carry risks such as serious infections and potential malignancies, which necessitate continuous monitoring. The benefits of sustained disease control often outweigh these risks for patients with severe, chronic conditions, but regular evaluations by a healthcare provider are essential to assess ongoing safety and efficacy.

Can Infliximab be taken with food?

Infliximab is administered intravenously, meaning it is infused directly into a vein. Therefore, food intake does not directly affect its absorption, efficacy, or safety. Patients can eat and drink normally before and after their infusion, unless specific instructions are given by their healthcare provider for other reasons (e.g., to manage potential nausea during infusion).

What should I do if I miss a dose of Infliximab?

If you miss an appointment for your Infliximab infusion, it is crucial to contact your healthcare provider or infusion center immediately. They will advise you on the best course of action, which typically involves rescheduling your infusion as soon as possible. Maintaining the prescribed dosing schedule is important to ensure optimal therapeutic levels of the medication and prevent disease flares.

Where can I buy Infliximab?

Infliximab is a powerful prescription-only medication and is not available for over-the-counter purchase. It must be prescribed by a qualified physician, typically a specialist in gastroenterology, rheumatology, or dermatology, and obtained through licensed pharmacies or infusion centers. Due to its complex administration and potential side effects, Infliximab therapy requires close medical supervision. It is strongly advised to obtain Infliximab only through legitimate and regulated medical channels to ensure its authenticity, safety, and proper handling.